OOIR: Observatory of International Research

Papers

(The median citation count of Current Opinion in HIV and AIDS is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Editorial introductions	51
Updates on bone health in people living with HIV: global impact, prediction tools, and treatment	38
The sounds of silencing: dynamic epigenetic control of HIV latency	35
Recent advances on anti-HIV chimeric antigen receptor-T-cell treatment to provide sustained HIV remission	34
Integrating socio-behavioral, ethics, community, and translational science considerations in HIV cure research	33
Future options for long-acting HIV treatment and prevention	30
HIV-associated tuberculosis in infants, children, and adolescents younger than 15 years: an update on the epidemiology, diagnosis, prevention, and treatment	29
Advancing HIV cure: insights from developing chronic hepatitis b therapies for functional cure	27
Editorial introductions	26
Harnessing natural killer cells to target HIV-1 persistence	25
Statins for primary cardiovascular disease prevention among people with HIV: emergent directions	24
Impact of early antiretroviral therapy, early life immunity and immune sex differences on HIV disease and posttreatment control in children	24
Editorial introduction	23
New latency-promoting agents for a block-and-lock functional cure strategy	22
Challenges towards an AIDS-free generation in Africa and Asia	20
Editorial introduction	19
Development of screening assays for use of broadly neutralizing antibodies in people with HIV	19
Pulse check: modern strategies for cardiovascular risk in women with detection and prevention in women with HIV	17
Persistent elite controllers as the key model to identify permanent HIV remission	16
Fc-mediated immunological mechanisms in HIV infection: a better understanding for improved therapeutic approaches	16
The double burden: navigating HIV co-infections with HCV, HBV, and Mtb	16
Public health surveillance and outbreak preparedness for mpox	15
Loneliness and social isolation in people with HIV	15
Editorial introduction	15
Estrogen depletion and immune activation and inflammation in women with HIV	15

A behavioral economics approach to enhancing HIV preexposure and postexposure prophylaxis implementation	15
Current insight into HIV-1 persistence from single-cell transcriptome profiling in acutely treated cohorts of infection	14
Stigma as a facilitator of the 2022 mpox outbreak	14
The origins of new SARS-COV-2 variants in immunocompromised individuals	14
Editorial introduction	13
Impact of coronavirus disease 2019 on co-morbidities in HIV	13
Defining multimorbidity in people with HIV – what matters most?	13
Integrating substance use services into HIV care: an underused implementation science opportunity	13
Balancing polypharmacy and comorbidity management: cardiovascular health	13
Hepatitis co-infection in paediatric HIV: progressing treatment and prevention	13
Obesity among women with HIV	12
The multifaceted nature of HIV tissue reservoirs	12
Aging of adult lifetime survivors with perinatal HIV	12
Viral and immune predictors of HIV posttreatment control	12
Role of follicular homing natural killer cells in HIV infection	12
Mpox and the impact on people with HIV	12
Frailty in people with HIV: a geriatric syndrome approach to aging with HIV	12
New vector and vaccine platforms: mRNA, DNA, viral vectors	12
Gender and sex considerations in HIV and bone health	11
Metabolic dysfunction-associated steatotic liver disease in people with HIV	11
Single-cell multiomic understanding of HIV-1 reservoir at epigenetic, transcriptional, and protein levels	11
Roadmap for spatial transcriptomics of HIV in tissues	11
Broadly neutralizing antibodies for HIV treatment and cure approaches	11
Single-cell sequencing technologies: a multiomics toolbox for investigating HIV-1 persistence	10
Use of implementation theories, models, and frameworks in PrEP implementation research from 2022–2025: innovation and participation	10
Host factors predisposing to kidney disease in people with HIV	10
The severity of COVID-19 across the spectrum of HIV	10
Maintain the gains: methods to evaluate the sustainability and scalability of HIV-related prevention, care, and treatment programs	10
Editorial introduction	9
HIV drug resistance in various body compartments	9
Editorial introductions	9
Editorial introductions	9
HIV and cardiovascular disease: the role of inflammation	9
Persistent HIV-1 transcription during ART: time to reassess its significance?	8
CD8+ T-cell responses in HIV controllers: potential implications for novel HIV remission strategies	8
Strategies to target the central nervous system HIV reservoir	8
Harnessing innate immunity: natural killer cells and innate immune responses in reservoir clearance	8
Innovative models of care supporting people aging with HIV	7
Natural killer cells in pediatric HIV cure strategies: from viral control to immunotherapeutics	7
Innate immune mechanisms in HIV elite controllers	7
Guiding HIV-1 vaccine development with preclinical nonhuman primate research	7
Contemporary issues in gynecologic and reproductive health for women with HIV	7
BACH2 effector-to-memory switch promotes HIV persistence and CAR-T efficacy	7
Vaccinal effect of HIV-1 antibody therapy: dream or reality?	7
The pathogenesis of obesity in people living with HIV	7
Mpox in 2026: what we knew, what we have learned, and what we still have to learn	7
Editorial introductions	7
Editorial introductions	7
HIV-1 subtypes and latent reservoirs	7
Causes and outcomes of hepatic fibrosis in persons living with HIV	7

Whole person HIV services: a social science approach	6
The role of analytical treatment interruptions in shaping HIV-specific immunity and HIV cure	6
Hepatitis C elimination in people with HIV: progress, gaps, and future directions	6
γc-cytokines in HIV Cure Research	6
Stem cell transplantation and allogeneic immunity: post treatment control or HIV cure?	6
Editorial introductions	6
Adolescents and young adults with HIV and unsuppressed viral load: where do we go from here?	6
What can spontaneous controllers, posttreatment controllers and postintervention controllers teach us about an HIV cure?	6
Towards an HIV cure: one cell at a time	6
HIV and comorbidities – the importance of gut inflammation and the kynurenine pathway	6
Role of islatravir in HIV treatment and prevention: an update	6
How could HIV-1 drug resistance impact preexposure prophylaxis for HIV prevention?	6
Evaluating immunotherapy as a pathway toward HIV cure	6
Progress with induction of HIV broadly neutralizing antibodies in the Duke Consortia for HIV/AIDS Vaccine Development	6
Scaling up preexposure prophylaxis to maximize HIV prevention impact	6
Towards a molecular profile of antiretroviral therapy-free HIV remission	6
Human papillomavirus infection among adolescents living with HIV: a focus on prevention	5
Promoting patient-centered care within HIV care settings in sub-Saharan Africa	5
It's all in the gut: the central role of the gut and microbiome in preventing disease progression in simian immunodeficiency viruses infected African nonhuman primates	5
Editorial: HIV and cardiovascular disease: recognizing and reducing disparities	5
Care of people aging with HIV in resource limited settings	5
Safety of oral tenofovir disoproxil - emtricitabine for HIV preexposure prophylaxis in adults	5
Cognitive impairment in persons with HIV: changing aetiologies and management strategies	5
Humanized mice for studying HIV latency and potentially its eradication	5
Editorial introductions	5
Cardiovascular disease risk in women living with HIV	5
Editorial introductions	5
Epidemiology of HIV drug resistance in low- and middle-income countries and WHO global strategy to monitor its emergence	5
Single cell analyses of the HIV reservoir in the CNS and CSF: recent insights and implications	5
The state of the art of adaptation strategies for HIV-related interventions	4
Targeting HIV myeloid and central nervous system reservoirs for HIV cure	4
Age at ART initiation and proviral reservoir size in perinatal HIV-1 infection: considerations for ART-free remission	4
Monocytes across life span in HIV infection: lights and shadows	4
Recent data on the role of antiretroviral therapy in weight gain and obesity in persons living with HIV	4
Editorial introduction	4
The power of ten in HIV remission: insights from hematopoietic stem cell transplantation	4
Immune checkpoint inhibition as a therapeutic strategy for HIV eradication: current insights and future directions	4
Pediatric immunotherapy and HIV control	4
The predictive value of macaque models of preexposure prophylaxis for HIV prevention	4
The female microbiome in HIV prevention, pathogenesis, and treatment	4
An evidence-based call for tailored interventions to support women with HIV who use substances	4
Delivery platforms for broadly neutralizing antibodies	4
Divide and conquer: broadly neutralizing antibody combinations for improved HIV-1 viral coverage	4
How nonhuman primate infant and mother-infant models can inform pediatric HIV-1 cure research	4
Stepping stones to cure in children with HIV	3
HIV cure: an acceptability scientific agenda	3
Cardiovascular health in people with perinatally acquired HIV – where do we stand?	3
Editorial introductions	3
Pulmonary comorbidities in people with HIV− the microbiome connection	3
Immune signatures and biomarkers of viral control in early-treated children with HIV: insights informing intervention	3
The vaginal microbiome and HIV transmission dynamics	3
Using single cell technologies to understand HIV latency models	3
Management of pain and other palliative needs in older people with HIV	3
Early intervention, lasting impact: benefits of early antiretroviral therapy and implications for posttreatment control	3
Features of functional and dysfunctional CD8+ T cells to guide HIV vaccine development	3
Barriers and facilitators related to COVID-19 vaccine acceptance and uptake among people living with HIV	3
Modeling the fallout: projecting the global impact of donor funding cuts on HIV prevention, treatment, and care	3
Geriatric syndromes in women living with HIV	3
Mycobacterium tuberculosis in HIV co-infection: a growing concern in Europe?	3
Understanding residual risk of cardiovascular disease in people with HIV	3
Post-intervention control in HIV immunotherapy trials	3
HIV T-cell immunogen design and delivery	3
Zika virus: an overview update	3
HIV and obesity: updates in management strategies	3
Public health services and intersectional stigma: a social sciences perspective with implications for HIV service design and delivery	3
Humoral immunity in HIV-1 post-treatment controllers	3
Transforming HIV prevention: the promise of long-acting preexposure prophylaxis in high HIV burden settings	3
Utilizing immunotherapy towards achieving a functional cure for HIV-1	3
Advancing considerations of context in the evaluation and implementation of evidence-based biomedical HIV prevention interventions: a review of recent research	3
The future of long-acting agents for preexposure prophylaxis	3
Human models that inform antiretroviral therapy-free remission with perinatally acquired HIV infection	3
A world of choices: preference elicitation methods for improving the delivery and uptake of HIV prevention and treatment	3
Editorial introductions	3